Survive and thrive: Funding opportunities and tax reliefs in the life sciences sector

9 July 2020

Gary Ashford, partner and chartered tax advisor at law firm Harbottle and Lewis, looks at tax issues around clinical research in the UK in an Expert View piece.

While COVID-19 presents one of the greatest challenges to civilization for many decades, the life sciences industry is being pushed forward into the shop window more than ever.

As scientists drive towards finding a vaccine, the additional publicity and spotlight on the industry, is welcome in a number of ways; it provides new opportunities for increased funding for companies in the industry, but also offers some welcome news for the public at large, in that some UK industries will thrive in these uncertain times.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK